vimarsana.com

Latest Breaking News On - Classical homocystinuria - Page 6 : vimarsana.com

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

/PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as.

United statesJim kastenmayerAeglea biotherapeuticsPiper sandlerExchange commissionJp morganEuropean medicines agencyDrug administrationPrnewswire aeglea biotherapeutics incAeglea biotherapeutics incInterim clinical dataPegtarviliase expectedFourth quarterCurrently dosing cohortClassical homocystinuriaMarketing authorization application

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase s Potential Role in Treatment

/PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to.

United statesMetabolic programProfessor of pediatrics at harvard medical schoolPrnewswire aeglea biotherapeutics incHeld thursdayClassical homocystinuriaSenior physicianBoston childrenHarvard medicalAeglea biotherapeutics

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase s Potential Role in Treatment

Event to be Held Thursday, October 27th at 10 AM ETAUSTIN, Texas, Oct. 19, 2022 /PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a cli.

United statesAeglea biotherapeuticsMetabolic programProfessor of pediatrics at harvard medical schoolEuropean medicines agencyPrnewswire aeglea biotherapeutics incAeglea biotherapeutics incHeld thursdayClassical homocystinuriaSenior physicianBoston childrenHarvard medicalRare pediatric diseaseBreakthrough therapyMarketing authorization applicationEuropean medicines

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

/PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as.

United kingdomUnited statesAeglea biotherapeuticsEuropean medicines agencyDrug administrationAeglea biotherapeutics incClassical homocystinuriaInvestigational new drugDrug designationPediatric diseaseRare pediatric diseaseBreakthrough therapyMarketing authorization applicationEuropean medicines

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

/PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as.

United statesJim kastenmayerAeglea biotherapeuticsMichael hanleyRussellj coxAnthony quinnPrnewswire aeglea biotherapeutics incPrioritizing resourcesOngoing phaseInterim clinical data expectedBoard memberStepped downHis current positionsExtend runwayClassical homocystinuriaDrug designation

vimarsana © 2020. All Rights Reserved.